Trial Profile
A Phase 1-2 Dose-Escalation and Safety Study of ADXS31-142 Alone and of ADXS31-142 in Combination With Pembrolizumab (MK-3475) in Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 22 Feb 2024
Price :
$35
*
At a glance
- Drugs ADXS 31142 (Primary) ; Pembrolizumab (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; First in man
- Acronyms KEYNOTE-046
- Sponsors Advaxis
- 08 Jun 2022 Results published in the Oncologist
- 08 Apr 2022 Results presented in an Advaxis Media Release.
- 08 Apr 2022 According to an Advaxis media release, data has been published online in The Oncologist.